Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study
01:01pm, Tuesday, 03'rd Feb 2026
SNY's phase III LEAP2MONO study meets all primary endpoints, with venglustat improving neurological symptoms in type 3 Gaucher disease patients.
UK industry body says Sanofi in breach over RSV therapy claims against Pfizer
08:42am, Monday, 02'nd Feb 2026
Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more effective than Pfizer's RSV vaccine, the industry's self-regulatory body said on Monday, resp
Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials
08:30am, Monday, 02'nd Feb 2026
Sanofi reports positive phase 3 results for oral venglustat in type 3 Gaucher disease, matching standard therapy outcomes and supporting plans for global regulatory filings.
Sanofi's genetic disorder drug shows mixed results in late-stage trials
01:02am, Monday, 02'nd Feb 2026
French drugmaker Sanofi said on Monday that its experimental genetic disorder treatment showed promise in a late-stage study of patients with a type of Gaucher disease, but failed to meet the main goa
Sanofi Q4 Earnings Call Highlights
02:02am, Saturday, 31'st Jan 2026
Sanofi (NASDAQ: SNY) executives told investors the company delivered "strong performance" in 2025 as it continued its shift toward what CEO Paul Hudson described as an "R&D-driven, AI-powered biopharm
Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease
07:00am, Friday, 30'th Jan 2026
Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy results from several clinical studies and real-world ev
Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
03:22pm, Thursday, 29'th Jan 2026
Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026
12:26pm, Thursday, 29'th Jan 2026
Sanofi SNY reported fourth-quarter 2025 adjusted earnings of 89 cents per American depositary share, which beat the Zacks Consensus Estimate of 84 cents. Earnings of €1.53 per share rose 16.8% on a
Sanofi Creeps Higher On 'Essentially In Line' Guidance For 2026
09:28am, Thursday, 29'th Jan 2026
Sanofi stock rose slightly early Thursday on better-than-expected earnings and in line guidance for the current year.
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
06:31am, Thursday, 29'th Jan 2026
Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, th
Sanofi to Launch $1.20 Billion Share Buyback
01:58am, Thursday, 29'th Jan 2026
The buyback comes as the French drugmaker said that its sales and earnings for the fourth quarter rose.
Sanofi targets high single digit sales growth in 2026, plans share buyback
01:33am, Thursday, 29'th Jan 2026
French drugmaker Sanofi said on Thursday it expects sales to grow by a high-single-digit percentage in 2026, banking on strong demand for its blockbuster asthma drug Dupixent and some newer medicines.
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to r
Cogent's New Stomach Cancer Treatment Cuts Progression Risk In Half, Gets Breakthrough Therapy Tag
10:06am, Monday, 26'th Jan 2026
The FDA granted breakthrough status to Cogent's GIST drug combo after a trial showed it cut disease progression or death risk by 50% compared with current treatment.
Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema
01:29am, Friday, 23'rd Jan 2026
Sanofi said its amlitelimab drug confirmed its potential to treat eczema in patients 12 years and older in two late-phase studies.
